This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cusi, K. Articles by DeFronzo, R. Search for Related Content PubMed PubMed Citation Articles by Cusi, K. Articles by DeFronzo, R.

Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance¹

Diabetes Division, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78284

Address all correspondence and requests for reprints to: Kenneth Cusi, M.D., Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas 78284-7886. E-mail: cusi{at}uthscsa.edu

The administration of recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycemia and insulin requirements in subjects with severe insulin resistance syndromes and in patients with type 2 diabetes mellitus (T2DM). However, the mechanisms responsible for the improved metabolic control are incompletely understood. One proposed mechanism is that rhIGF-I therapy in T2DM may bypass early defects in insulin action (i.e. signal transduction), leading to improved hepatic and/or peripheral insulin sensitivity. To test this hypothesis, we used the euglycemic insulin clamp to measure the response to 7 days of rhIGF-I therapy (80 µg/kg, sc, twice daily) in eight poorly controlled T2DM subjects. rhIGF-I significantly improved fasting (203 ± 12 vs. 134 ± 14 mg/dL; P < 0.01) and day-long (0800–1700 h; 234 ± 11 vs. 153 ± 10 mg/dL; P < 0.01) plasma glucose levels. Basal endogenous glucose production decreased from 3.2 ± 0.2 to 2.7 ± 0.2 mg/kg lean body mass ·min (P < 0.03) despite a concomitant decline in the fasting plasma insulin concentration from 13 ± 5 to 5 ± 1 µU/mL (P < 0.01). The decrement in basal endogenous glucose production was closely correlated with the decrement in fasting plasma glucose concentration (r = 0.78; P < 0.01). Whole body insulin-stimulated glucose disposal increased by 27% (from 5.6 ± 0.8 to 7.1 ± 0.8 mg/kg lean body mass·min; P < 0.01), but remained well below that observed in age- and weight-matched healthy subjects. The effects of rhIGF-I on endogenous glucose production and peripheral insulin sensitivity resemble those observed with intensified insulin regimens in T2DM. We conclude that 7 days of sc rhIGF-I improves glucose control by improving hepatic and muscle insulin sensitivity, but it remains markedly abnormal. This indicates that an intrinsic defect(s) responsible for insulin resistance in T2DM cannot be overcome by rhIGF-I treatment.

This article has been cited by other articles:

				D. R. Clemmons, M. Sleevi, G. Allan, and A. Sommer Effects of Combined Recombinant Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein-3 in Type 2 Diabetic Patients on Glycemic Control and Distribution of IGF-I and IGF-II among Serum Binding Protein Complexes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2652 - 2658. [Abstract] [Full Text] [PDF]

				J.-W. Chen, M. F Nielsen, A. Caumo, H. Vilstrup, J. S. Christiansen, and J. Frystyk Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur. J. Endocrinol., August 1, 2006; 155(2): 285 - 292. [Abstract] [Full Text] [PDF]

				L. J. Murphy Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology, June 1, 2006; 147(6): 2616 - 2618. [Full Text] [PDF]

				P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, S. Yakar, and D. LeRoith Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus Endocrinology, June 1, 2006; 147(6): 2619 - 2630. [Abstract] [Full Text] [PDF]

				S. A Bayol, B. H Simbi, and N. C Stickland A maternal cafeteria diet during gestation and lactation promotes adiposity and impairs skeletal muscle development and metabolism in rat offspring at weaning J. Physiol., September 15, 2005; 567(3): 951 - 961. [Abstract] [Full Text] [PDF]

				K. Yuen, J. Frystyk, M. Umpleby, L. Fryklund, and D. Dunger Changes in Free Rather Than Total Insulin-Like Growth Factor-I Enhance Insulin Sensitivity and Suppress Endogenous Peak Growth Hormone (GH) Release following Short-Term Low-Dose GH Administration in Young Healthy Adults J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3956 - 3964. [Abstract] [Full Text] [PDF]

				T. Pratipanawatr, W. Pratipanawatr, C. Rosen, R. Berria, M. Bajaj, K. Cusi, L. Mandarino, S. Kashyap, R. Belfort, and R. A. DeFronzo Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1360 - E1368. [Abstract] [Full Text] [PDF]